How Long Before GE, Celera Visualize Cash from Their New Imaging Deal? | GenomeWeb

General Electric and Celera Genomics this week disclosed the start of a long-term collaboration aimed at developing imaging agents that would help physicians identify certain cancers sooner and more accurately.

The deal, which will initially focus on four kinds of tumors and the proteins on the surface of cells, would also empower Celera Diagnostics to develop molecular diagnostics based on these agents, which could be used to identify at-risk populations or to pinpoint disease onset or severity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.